Genzyme rated at buy by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh gave Genzyme Corp. a buy rating and an $80 price target on higher-than-expected Renagel and Myozyme sales in the third quarter. Synvisc sales were negatively impacted by Euflexxa, new to the viscosupplementation market. Shares of the Cambridge, Mass.-based biotechnology company were up 39 cents, or 0.58%, at $67.29. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.